A Phase IIb, Long-Term Extension Study to Evaluate the Safety and Efficacy of HB0034 in the Treatment of Adult Subjects With Generalized Pustular Psoriasis
Latest Information Update: 21 Feb 2025
At a glance
- Drugs HB 0034 (Primary)
- Indications Generalised pustular psoriasis
- Focus Adverse reactions
- Sponsors Huaota Biopharmaceuticals
Most Recent Events
- 19 Sep 2024 Status changed from not yet recruiting to recruiting.
- 04 Jul 2024 New trial record